EGFR and non-small cell lung carcinoma: A global, multicenter, randomized, double-blind Phase III trial (NCT05184712) (17, 18) was conducted to assess the efficacy of Ivonescimab combined with chemotherapy compared to chemotherapy alone in patients with EGFR-mutated, locally advanced, or metastatic NSCLC who had progressed following third-generation EGFR-TKI therapy.